Denali Therapeutics Inc. Cost of Revenue
Denali Therapeutics Inc. (DNLI) reported Cost of Revenue of $93.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- Denali Therapeutics Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $93.00K.
- Denali Therapeutics Inc. cost of goods and services sold for the quarter ending 2025-06-30 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month |
|---|---|---|
| 2026-06-30 | $93.00K 10-Q · filed 2026-08-06 | $93.00K 10-Q · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |